Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

FDA Approves FoundationOne CDx as Pemigatinib Companion Diagnostic in FGFR2+ Cholangiocarcinoma

April 21st 2020

The FDA has approved FoundationOne CDx as the registrational companion diagnostic for pemigatinib, which the agency recently approved for the treatment of adult patients with previously treated, unresectable locally advanced or metastatic FGFR2+ cholangiocarcinoma.

Dr. Husain on the Evolution of Liquid Biopsies in Lung Cancer

April 20th 2020

Hatim Husain, MD, discusses the evolution of liquid biopsies in lung cancer.

Dr. Hudson on the Utility of Liquid Biopsy in Lung Cancer

April 16th 2020

Kathryn E. Hudson, MD, discusses the utility of liquid biopsy in lung cancer.

Genomic Profiling Shows Clinical Utility in Select Sarcomas

April 15th 2020

Comprehensive genomic profiling can be successfully performed in the majority of patients with sarcoma, depending on the tumor location and tissue subtype, which can impact treatment decisions and patient outcomes.

Innovative plasmaMATCH Trial Displays Feasibility With ctDNA in Breast Cancer

April 15th 2020

Joyce A. O'Shaughnessy, MD, discusses the design and findings of the plasmaMATCH trial and ongoing research with targeted therapy in breast cancer.

Dr. Alshaygy on Precision Medicine Research in TGCT

April 15th 2020

Ibrahim S. Alshaygy, MD, MSC, discusses precision medicine research in tenosynovial giant cell tumor.

Dr. Dimou on Progress Made in ALK+ Lung Cancer Treatment

April 15th 2020

Anastasios (Tassos) Dimou, MD, discusses the progress made in the treatment of patients with ALK-positive lung cancer.

Liquid Biopsy Detects Alterations That Confer Resistance to Alpelisib in HR+ Breast Cancer

April 15th 2020

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors in patients with hormone receptor–positive metastatic breast cancer.

Other Trials of Interest in Renal Cancers

April 14th 2020

Promising Second-Line Therapies for mRCC

April 14th 2020

Progress in First-Line mRCC

April 14th 2020

Combination Therapies to Overcome Resistance in mRCC

April 14th 2020

VEGF TKI Therapy After I/O in mRCC

April 14th 2020

Second-Line Therapy After I/O in mRCC

April 14th 2020

mRCC: Resistance to VEGF and I/O

April 14th 2020

IMDC Criteria and Targeted Therapy in mRCC

April 14th 2020

VEGF-TKI Therapy in First-Line mRCC

April 14th 2020

SBRT in Combination With Ipilimumab/Nivolumab in mRCC

April 14th 2020

Ipilimumab/Nivolumab for Favorable-Risk mRCC

April 14th 2020

iRECIST Criteria and First-Line Treatment of mRCC

April 14th 2020